Hans T. Schambye is an accomplished biotech executive currently serving as the President and CEO of Galecto, Inc., where they lead advanced programs in fibrosis and cancer. With a solid academic foundation as a Medical Doctor and a PhD in Molecular Pharmacology, they possess extensive expertise in drug discovery, development, and corporate strategy. Hans previously held prominent roles as Chairman and Board Member for various biotech companies, including Rose Pharma, Forward Pharma, and Gastrotech Pharma. Additionally, they are fluent in Danish and English, and proficient in German and French.
This person is not in any teams
This person is not in any offices